Superb-seq Maps CRISPR Edits in Single Cells

A new Salk Institute method detects both intended and unintended CRISPR edits and their effects on gene activity, one cell at a time.

Updated on Nov. 16, 2026 in Life Sciences

Superb-seq Maps CRISPR Edits in Single Cells

Salk Institute scientists designed Superb-seq, a method that reads out CRISPR edits and the gene expression changes they cause at single-cell resolution. The study was published in Nature Methods on November 16, 2026.

Why it matters

CRISPR/Cas9 can make off-target edits to parts of the genome never meant to be touched, and existing methods show where such edits sit but not which cells carry them or how they change cell behavior. Superb-seq addresses that gap for researchers and for developers of genome-based therapies.

Superb-seq combines Cas9 editing, a short edit-reporting DNA sequence, and single-cell RNA sequencing, whereas its predecessor Perturb-seq reads guide RNAs but not the resulting edits. Its performance beyond the three tested cell lines has not been reported.

The players

Salk Institute

The Salk Institute for Biological Studies is a nonprofit research institution in La Jolla, California, known for its work in the life sciences.

The details

Superb-seq integrates Cas9 editing, a short edit-reporting DNA sequence and single-cell RNA sequencing to capture individual edits and their effect on gene expression. It was tested on 34,000 cells from three cell lines and detected gene expression changes caused by genome edits that existing edit detection methods cannot see.

Timeline

  1. 2012: CRISPR/Cas9 is discovered to function as molecular scissors.

  2. 2023: The first FDA-approved CRISPR-based therapy is developed to treat sickle cell disease and beta thalassemia.

  3. November 16, 2026: The Superb-seq study is published in Nature Methods.

The Big Picture

CRISPR/Cas9, discovered in 2012 to function as molecular scissors, has moved from the lab into an approved therapy, and that shift raised the stakes of knowing where its edits land. Superb-seq extends the toolkit by linking each edit to its effect on individual cells, the kind of verification the field needs as genome therapies advance.

Superb-seq could help establish the safety of genome therapy candidates early in development, and could reveal how far off-target edits affect findings in tens of thousands of CRISPR papers. These uses are projections that have not yet been demonstrated.

The takeaway

Verifying where a genome edit lands and what it does inside each cell is becoming as important as making the edit itself. Researchers designing CRISPR experiments may find single-cell edit readouts a useful check on unintended effects.

Further reading

Explore more research in our Life Sciences section.